OSCR vs UNH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

UNH is the larger of the two ($357.88B market cap): the incumbent the market prices for continued execution (17.12x forward earnings, beta 0.52). OSCR is the smaller challenger ($10.17B), cheaper on forward earnings (14.19x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

OSCR vs UNH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricOSCRUNHWhat it tells you
Market cap$10.17B$357.88BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E14.1917.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E14.5522.80Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta2.490.52Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range79% of range70% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.573.65How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: OSCR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how OSCR and UNH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. OSCR and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined OSCR and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Oscar Health (OSCR) do?

Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers. The vast majority of its money comes from premiums on individual and family health plans sold through the Affordable Care Act (ACA) public marketplaces, where by early 2026 it had grown to roughly 3.2 million members, up about 56% year over year, making it one of the larger players on the exchanges. Alongside the insurance business it runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment tools; that platform revenue is small today but growing faster than premiums and carries higher margins. The company was founded in 2012 by Mario Schlosser, Kevin Nazemi, and Joshua Kushner, and is now led by chief executive Mark Bertolini, a former Aetna CEO.

Full OSCR guide

What does UnitedHealth Group (UNH) do?

UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.

Full UNH guide

OSCR vs UNH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • OSCR drivers: Membership growth and share gains; Turn to profitability.
  • UNH drivers: Optum growth engine; Medicare Advantage scale.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is policy. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.

OSCR or UNH: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick OSCR if you believe its drivers more; UNH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the OSCR and UNH guides.

OSCR vs UNH: the full fundamentals

OSCR. Figures are approximate and tied to the asOf date; verify live numbers before acting. OSCR has more than doubled in 2026, yet it still trades at about 0.66x trailing sales and ~15x forward earnings, low for a company growing revenue 70%, because the market prices in ACA-policy risk and expected second-half losses. Analysts' mean target of ~$36 sits only about 11% above the current price.

UNH. The trailing P/E of about 26x is inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 17x, closer to its historical range. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. The stock has recovered a large part of its 2025 decline, which leaves less of a discount for regulatory and cost risk than a year ago.

Headline figures (approximate, October 2026): OSCR shows revenue (ttm) ~$15.3 billion, revenue growth (q2 2026, yoy) ~70% (Q2 revenue ~$4.88 billion), net income (ttm) ~$551 million (EPS ~$1.29); Q2 2026 ~$362 million, margins Operating ~8%, net ~3.6%; UNH shows revenue (ttm) ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year, operating margin ~5.8% (net margin ~3.5%), net income (ttm) ~$15.9 billion (sensitive to medical costs), eps ~$15.55 trailing; Q3 2026 $4.69 vs $4.14 consensus.

The bottom line: OSCR vs UNH

OSCR and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined OSCR and UNH exposure against your real portfolio. It is not an investment adviser.

Wondering how OSCR or UNH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Oscar Health

Ask Walnut's AI anything about OSCR and see how it fits what you own.

FAQ

What is the difference between OSCR and UNH?

+

Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers. UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is OSCR or UNH the better stock?

+

Neither is universally better. UNH is the larger incumbent; OSCR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, OSCR or UNH?

+

On forward P/E (as of November 2026), OSCR trades at 14.19x and UNH at 17.12x, so OSCR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both OSCR and UNH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of OSCR vs UNH?

+

OSCR: The dominant risk is policy. Oscar is a near pure-play ACA marketplace insurer, so the status of enhanced federal premium tax credits is an existential-level variable: without them, marketplace premiums could more than double for many enrollees, healthier members may drop coverage, and the remaining risk pool would skew sicker and more expensive. Oscar itself took a weighted-average rate increase near 28% for 2026 partly to account for worsening morbidity, and October 2026 coverage of managed-care stocks has flagged election and healthcare-cost pressure. Results are also highly seasonal: 2025 swung from profit early in the year to losses of ~$137 million in Q3 and ~$353 million in Q4, and analysts again expect losses in Q3 and Q4 2026. On top of that, Oscar competes against far larger, better-capitalized insurers, and any spike in medical costs, adverse regulatory change, or execution stumble hits a company still proving it can stay profitable across a full year. After a ~118% rise in 2026, the stock trades near its 52-week high of ~$35, and the average analyst rating is hold. UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. The 2026 recovery also raises the bar: at roughly 17x forward earnings the stock now prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell OSCR or UNH; figures are approximate and dated (as of November 2026). Verify current data before investing.